Dive Into the New Age of Nanoparticle Formulation and Medical Devices
Better & Faster Biotechnology
AI-Driven Diagnostic Systems and Clinical Predictive Modeling
A goal of our organization is to deliver clinical-grade diagnosis and treatment planning software tailored for periodontal professionals. We aim to synthesize critical clinical data—including pocket depths, plaque indices, and bleeding metrics—with AI-driven predictive insights to facilitate faster, more accurate disease staging and highly personalized care.
​
Furthermore, we are committed to reinventing periodontal care through the our consumer application. By integrating longitudinal data tracking with advanced medical device technology and computer vision, we seek to disrupt the global market and pioneer a future focused on predictive, preventative oral health.
Nanoparticle Formulation Technology
Accelerated Drug Development Strategy
By leveraging our product development expertise and core technology, we mitigate the high costs and risks associated with basic research on new chemical entities. Instead, we reformulate readily available compounds with established safety and efficacy profiles for oncology and periodontal treatments. This strategic approach accelerates drug development and significantly condenses regulatory approval timelines.
​
Advanced Periodontal Technologies
Our finalized periodontal products utilize PLGA polymer-based nanoparticle drugs for subgingival application. PLGA is an FDA-approved, biodegradable, and highly biocompatible polymer.
​
Pipeline Optimization & Formulation Expertise
Beyond periodontal care, our early-stage pipeline includes promising oral and intravenous nanoparticle therapeutics. To ensure safety and efficacy, our team of PhD formulation scientists optimizes drug candidates across several critical checkpoints:
-
Biocompatibility & Toxicity: Ensuring safe interaction with human tissue.
-
Drug Delivery: Optimizing drug loading and controlled release.
-
Stability: Enhancing nanoparticle storage and shelf-life.
-
Targeting: Improving biodistribution, organ/tissue selectivity, and cellular internalization.
-
Biodegradability: Guaranteeing safe breakdown within the body.
Driving Clinical Trial Success
Mastering these checkpoints ensures our polymer-based formulations are safe and highly effective. Ultimately, our deep formulation expertise provides a reliable blueprint for early-stage nanotherapeutic development, maximizing the success rate of our formulations as they enter clinical trials.
Versatility in Anesthetic Injections
Our patented technology and business objective is to reduce pain and efficiency of dental local anesthetic injections for patients. Our primary focus is on the development, regulatory approval, and commercialization of an improved local dental anesthetic drug that is less painful, faster-acting, and more reliable.
​
Our success is based on the comprehensive development of a winning regulatory strategy to help build a crucial framework for the overall development plan and aid in determining the fastest execution.
Multiple-dose, Automated-dosing and Single use-disposable Periodontal Devices
Our research is driving tangible innovations that will redefine the periodontal market. Through our active projects, we are developing an advanced platform for localized therapy that delivers faster, more accurate, and highly effective periodontal treatments.
​
Backed by our mission of "helping people live longer," our patented devices leverage advanced technology to help patients maintain healthy gums for life.
Since 2012, we have been dedicated to solving the most fundamental challenges in periodontal care. By channeling our transformative technologies through a comprehensive regulatory strategy, we are significantly improving the entire periodontal workflow. ​
We develop and integrate FDA regulated software, drug nanoparticles formulation and medical devices with the end user ecosystem
Medical diagnosis and planning AI software has taken the healthcare industry by storm. Our business focus is on improved drugs, new diagnostic and planning methods, drug delivery systems, and medical devices that offer the hope of better treatment and care
Empower Growth
In 2023, we received FDA clearance on our first standalone medical device. In 2027 we are expected to receive FDA approval for our first two finished periodontal drug products.
As our team prepares for success to meet the high demand for periodontal disease around the Globe, we continue working on expanding our clean facility room in Florida to meet expected demand domestic and international demand.
​
In the U.S., “one out of every two American adults aged 30 and over has periodontal disease” according to the Centers for Disease Control and Prevention (CDC). Across the globe, periodontal disease is the single most prevalent chronic infectious disease.
